Biotechnology firm Moderna has provided update on the impact of the Covid-19 coronavirus pandemic on its clinical development activities and business operations.
The company is set to pause recruitment of new participants for its Phase I trials of mRNA-3704 and mRNA-3927 in rare diseases methylmalonic acidemia and propionic acidemi, respectively.
Moderna’s decision is based on a risk-based analysis being used to review new participant enrolment and site initiation for its ongoing clinical trials.
The company also decided to temporarily halt its age de-escalation trial of pediatric respiratory vaccine. The ongoing Phase II CMV trial of mRNA-1647 and Phase I Zika trial mRNA-1893 are fully enrolled but some participants may not get the